Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma.

Annals of hematology - 1 Dec 2023

Ebid Osama Abd El Hameed, Ezz El Arab Lobna R, Saad Amr S, Ezz El Din Mai, Mostafa Nermeen, Swellam Menha

Abstract excerpt

Diffuse large B cell lymphoma (DLBCL) is the most common subtype of lymphoma. It is a highly heterogeneous lymphoid neoplasm, with variations in gene expression profiles and genetic alterations. MYD88 and TP53 genes are common to be expressed and mutated in DLBCL patients with controversy regarding their role in prognosis and survival. This study aims to determine the predictive and prognostic role of MYD88 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to Prognosis

Share to Tumor Suppressor Protein p53

Share to Viral-associated cancers and disorders

Source

Open in PubMed Open full text

Identifiers

PMID: 37658234
DOI: 10.1007/s00277-023-05420-1
PMCID: PMC10640512

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma.PMID 37658234Read ↗

Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.Semantic proximity Read ↗

MYD88 <sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapySemantic proximity Read ↗

MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Prognostic Analysis of Diffuse Large B-Cell Lymphoma Patients Based on Clinical Characteristics, TP53 Mutation Status, and Number of Co-mutated GenesSemantic proximity Read ↗

Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targetsSemantic proximity Read ↗

Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.Semantic proximity Read ↗

A Novel CD58 Mutation-Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients.Semantic proximity Read ↗

Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.Semantic proximity Read ↗

Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.Semantic proximity Read ↗

Prognostic Impact of TP53 Mutations in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.